All In Biotech

Drug Trial Radar · NCT04185883

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

610

Actual

Start

Dec 17, 2019

Primary completion

Dec 17, 2026

Study completion Dec 5, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Dec 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

Conditions

  • Advanced Solid Tumors
  • Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Interventions

  • SotorasibDrug

    Sotorasib administered orally as a tablet.

  • TrametinibDrug

    Trametinib administered orally as a tablet.

  • RMC-4630Drug

    RMC-4630 administered orally as a capsule.

  • AfatinibDrug

    afatinib administered orally as a tablet.

  • PembrolizumabDrug

    pembrolizumab administered as an intravenous (IV) infusion.

  • PanitumumabDrug

    Panitumumab administered as an IV infusion.

  • Carboplatin, pemetrexed, docetaxel, paclitaxelDrug

    Carboplatin, pemetrexed, docetaxel administered as an IV infusion.

  • AtezolizumabDrug

    Atezolizumab administered as an IV injection.

  • PalbociclibDrug

    Palbociclib administered orally as a tablet.

  • MVASI® (bevacizumab-awwb)Drug

    MVASI® (bevacizumab-awwb) administered as an IV infusion.

  • TNO155Drug

    TNO155 administered orally as a capsule.

  • IV Chemotherapy (Regimen 1)Drug

    Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.

  • IV Chemotherapy (Regimen 2)Drug

    IV chemotherapy combination of leucovorin administered as an IV injection, 5-FU administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.

  • BI 1701963Drug

    BI 1701963 administered orally

  • AMG 404Drug

    AMG 404 administered as an IV infusion.

  • EverolimusDrug

    Everolimus administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: 12 Months
  2. Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: 12 Months
  3. Number of Participants with Treatment-related Adverse EventsTime frame: 12 Months
  4. Number of Participants with Clinically Significant Changes in Vital SignsTime frame: 12 Months
  5. Number of Participants with Clinically Significant Changes in ECG MeasurementsTime frame: 12 Months
  6. Number of Participants with Clinically Significant Changes in Laboratory Test ValuesTime frame: 12 Months

Locations

90 sites in 13 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates Professional Corporation

    Tucson, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • Loma Linda University Cancer Center

    Loma Linda, California

  • University of Southern California, Norris Comprehensive Cancer Center

    Los Angeles, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of California San Francisco Mission Bay Campus

    San Francisco, California

  • University of California Los Angeles

    Santa Monica, California

  • Rocky Mountain Cancer Centers Denver Midtown

    Denver, Colorado

  • Sarah Cannon Research Institute

    Denver, Colorado

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Norwalk Hospital

    Norwalk, Connecticut

  • Memorial Cancer Institute

    Pembroke Pines, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Johns Hopkins University

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion)

    Detroit, Michigan

  • Washington University

    St Louis, Missouri

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Duke University

    Durham, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Providence Portland Medical Center

    Portland, Oregon

  • Oregon Health and Science University

    Portland, Oregon

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Gibbs Cancer Center and Research Institute - Spartanburg

    Spartanburg, South Carolina

  • Avera Cancer Institute

    Sioux Falls, South Dakota

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.